Coumarin-based prodrugs 2. Synthesis and bioreversibility studies of an esterase-sensitive cyclic prodrug of DADLE, an opioid peptide

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 23, 1996, Pages 2823-2826

  Wang, Binghe ^a   Wang, Wei ^a   Zhang, Huijuan ^a   Shan, Daxian ^a   Smith, Terrill D ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COUMARIN DERIVATIVE; CYCLOPEPTIDE; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; ESTERASE; OPIATE PEPTIDE; PRODRUG;

ARTICLE; BIOAVAILABILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TECHNIQUE;

EID: 0030568115     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(96)00526-4     Document Type: Article

References (24)

1. 1. Wang, B.; Zhang, H.; Wang, W. Bioorg. Med. Chem. Lett. 1996, 6, 945.
2. 2. Part of this work was performed at the College of Pharmacy, University of Oklahoma Health Sciences Center.
3. 3. Visiting professor from Department of Chemistry, University of Central Oklahoma, Edmond, OK.
4. 4. Oliyai, R.; Stella, V. J. Annu. Rev. Pharmacol. Toxical. 1993, 32, 521.
5. 5. (a) Wang, B.; Gangwar, S.; Pauletti, G. M.; Siahaan, T. J.; Borchardt, R. T. J. Org. Chem. 1996, manuscript submitted.
6. (b) Pauletti, G. M.; Gangwar, S.; Wang, B.; Siahaan, T. J.; Borchardt, R. T. Pharm. Res. 1997, in press
7. (c) Pauletti, G. M.; Gangwar, S.; Okumu, F. W.; Siahaan, T. J.; Stella, V. J.; Borchardt, R. T. Pharm. Res. 1996, in press.
8. (d) Gangwar, S.; Pauletti, G. M.; Siahaan, T. J.; Stella, V. J.; Borchardt, R. T. J. Org. Chem. 1996, manuscript submitted.
9. 6. Hughes, J.; Smith, T. W.; Kosterlitz, H. W.; Fothergill, L. A.; Morgan, B. A.; Morris, H. R. Nature (London) 1975, 258, 577.
10. 7. Bedded, C. R.; Clark, R. B.; Hardy, G. W.; Lowe, L. A.; Ubatuba, F. B.; Vane, J. R.; Wilkinson, S.; Chang, K. J.; Cuatrecasas, P.; Miller, R. J. Proc. Roy. Soc. London 1977, 198, 149.
11. 8. Schiller, P. W.; Nguyen, T. M.-D.; Maziak, L.; Lemieux, C. Biochem. Biophys. Res. Commun. 1985, 127, 558.
12. 9. Hershfield, R.; Schmir, G. L. J. Am. Chem. Soc. 1973, 95, 7359.
13. 10. Hershfield, R.; Schmir, G. L. J. Am. Chem. Soc. 1973, 95, 8032.
14. 11. Garrett, E. R.; Lippold, B. C.; Mielck, J. B. J. Pharm. Sci. 1971, 60, 396.
15. 12. Lippold, B. C.; Garrett, E. R. J. Pharm. Sci. 1971, 60, 1019.
16. 13. National Toxicology Program "Toxicology and Carcinogenesis Studies of Coumarin", U.S. Department of Health and Human Services: Public Health Service and National Institutes of Health, 1993.
17. 14. Bodanszky, M.; Bodanszky, A. The Practice ofPeptide Synthesis; Springer-Velag: New York, 1984.
18. 15. Diago-Meseguer, J.; Palomo-Coll, A. L.; Fernandez-Lizarbe, J. R.; Zugaza-Bilbao, A. Synthesis 1980, 547.
19. 8: 698.3190; Found: 698.3209.
20. 17. Bundgaard, H. Design of Prodrugs: Elsevier: Amsterdam, 1985.
21. 18. Amsberry, K. L.; Gerstenberger, A. L.; Borchardt, R. T. Pharm. Res. 1991, 8, 455.
22. 19. Bundgaard, H.; Klixbull, U.; Falch, E. Int. J. Pharmaceut. 1986, 29, 19.
23. 20. Results were average of triplicates.
24. 21. HPLC analysis conditions for Figure 1. Solvent: A = methanol, B = water; gradient: 50% to 90% A over 15 min, then 90% to 100% A over 3 min. HPLC analysis conditions for Figure 2. Solvent: A = 0.1% TFA in acetonitrile/water (3:1), B = 0,1% TFA in water; gradient: 30% to 50% A over 15 min.